An update on emerging drugs in osteosarcoma: towards tailored therapies?

Claudia Maria Hattinger, Maria Pia Patrizio, Federica Magagnoli, Silvia Luppi, Massimo Serra

Research output: Contribution to journalArticle

Abstract

Introduction: Current treatment of conventional and non-conventional high-grade osteosarcoma (HGOS) is based on the surgical removal of primary tumor and, when possible, of metastases and local reccurrence, together with systemic pre- and post-operative chemotherapy with drugs that have been used since decades. Areas covered: This review is intended to summarize the new agents and therapeutic strategies that are under clinical evaluation in HGOS, with the aim to increase the cure probability of this highly malignant bone tumor, which has not significantly improved during the last 30-40 years. The list of drugs, compounds and treatment modalities presented and discussed here has been generated by considering only those that are included in presently ongoing and recruiting clinical trials, or which have been completed in the last 2 years with reported results, on the basis of the information obtained from different and continuously updated databases. Expert opinion: Despite HGOS is a rare tumor, several clinical trials are presently evaluating different treatment strategies, which may hopefully positively impact on the outcome of patients who experience unfavorable prognosis when treated with conventional therapies.

Original languageEnglish
Pages (from-to)153-171
Number of pages19
JournalExpert Opinion on Emerging Drugs
Volume24
Issue number3
Early online dateAug 14 2019
DOIs
Publication statusPublished - Sep 2019

    Fingerprint

Keywords

  • Osteosarcoma
  • biomarkers
  • chemotherapy
  • drug resistance
  • pharmacogenomics
  • tailored therapy
  • targeted drugs

Cite this